Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Brindisi, Italy Clinical Trials

A listing of Brindisi, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (39) clinical trials

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

This is a prospective, multicenter, two-arm randomized phase II screening trial34 in young patients (18-65 years) affected by relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) at diagnosis, eligible to high-dose therapy. Aim of the study is to to assess whether the addition of Bortezomib to R-DHAP is more promising than standard ...

Phase

0.0 miles

Learn More »

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

The purpose of this Phase IIIb study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer.

Phase

0.0 miles

Learn More »

Chart Review of Repatha in Subjects With Hyperlipidaemia

Review of clinical characteristics of patients who are prescribed Repatha and how their treatment is managed.

Phase N/A

0.0 miles

Learn More »

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

The purpose of this study is to find out what effects a new drug, pembrolizumab has on this type of cancer and if it can offer better results than standard pemetrexed and platinum-based chemotherapy alone. This study will also look at side effects and how the treatments impact quality of ...

Phase

0.0 miles

Learn More »

Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis

Stroke is the most common cause of seizures in the elderly and seizures are among the most common sequelae of stroke. About 10% of patients experience seizures since stroke onset up to several years (Silverman 2002). Arbitrarly a cut point of 2 weeks divide early seizures from late seizures (Honey ...

Phase

0.0 miles

Learn More »

The Clinical Evaluation of the Dose of Erythropoietins Trial

Phase III pragmatic, randomized-controlled trial comparing different doses of ESAs in patients with renal anaemia. Study Sample: Total of 900 participants from Italy Background and Rationale: Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents ...

Phase

0.0 miles

Learn More »

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting. The Primary Objective is to describe carfilzomib utilisation in routine clinical practice, including dosage, administration schedule, regimen, duration of ...

Phase N/A

0.0 miles

Learn More »

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

This post authorization safety study is designed as prospective non interventional study for patients with newly diagnosed multiple myeloma who are not eligible for transplant. The objective is to compare the incidence of cardiovascular events between patients treated with a first-line lenalidomide containing regimen and those treated with a first-line ...

Phase N/A

0.0 miles

Learn More »

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Phase

0.0 miles

Learn More »

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Acute Lymphoblastic Leukemia

Eligible patients with CD19+ Ph- BCP ALL (Philadelphia-negative B-cell precursor acute lymphoblastic leukemia) will receive homogeneous supportive care, chemotherapy and blinatumomab immunotherapy, and will be homogeneously analyzed for response at prefixed time points from induction day 1. For risk-oriented therapy, patients in complete remission (CR) will be stratified by risk ...

Phase

0.0 miles

Learn More »